drugset / Trial / NCT04072861
A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease
Non-randomizedSequentialOpen-labelPrevention
Summary
This is a Phase 1b, single-center, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of RBT-9 in healthy volunteers and in subjects with Stage 3/4 CKD.
Timeline
- Start
- 2019-03-31
- Primary completion
- 2020-07-31
- Completion
- 2020-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RBT-9 | Small molecule | 9 mg | Intravenous |
| Subject | RBT-9 | Small molecule | 27 mg | Intravenous |
| Subject | RBT-9 | Small molecule | 90 mg | Intravenous |